Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie

在艾伯维以109亿美元收购Apogee之后，领导团队为Paragon带来了经过验证的公司建设和药物开发经验

Velaris is the ninth company launched around Paragon-discovered assets and the first supported by Paragon's expanded leadership team

Velaris 是围绕 Paragon 发现的资产而成立的第九家公司，也是首家由 Paragon 扩大后的领导团队提供支持的公司。

BOSTON

波士顿

,

，

Oct. 13, 2026

2026年10月13日

/PRNewswire/ -- Paragon Labs (together with related entities, 'Paragon'), a biotechnology company focused on the discovery and development of differentiated biologics, today announced that members of the former senior leadership team of Apogee Therapeutics ('Apogee') have joined Paragon. The expanded leadership team will support Paragon-discovered assets through clinical development and help build new companies around promising therapeutic candidates, starting with Velaris Therapeutics, a biotechnology company focused on developing therapies for pulmonary hypertension and related cardiopulmonary diseases..

/美通社/ -- 专注于发现和开发差异化生物制品的生物技术公司 Paragon Labs（连同相关实体，统称“Paragon”）今日宣布，Apogee Therapeutics（“Apogee”）前高级领导团队成员已加入 Paragon。扩建后的领导团队将支持 Paragon 发现的资产通过临床开发阶段，并围绕有前景的治疗候选药物帮助建立新公司，首先成立的是 Velaris Therapeutics，这是一家专注于开发肺动脉高压及相关心肺疾病疗法的生物技术公司。

The team is led by Michael Henderson, M.D., Chief Executive Officer, and Carl Dambkowski, M.D., Head of R&D, alongside Dan Mulreany, Chief Business and Financial Officer; Matt Batters, J.D., Chief Legal Officer; and Emily Cox, Chief People Officer. The team previously worked together at Apogee, where they helped advance five Paragon-discovered assets into clinical development until Apogee's 2026 acquisition by AbbVie for over $10.9 billion..

该团队由首席执行官迈克尔·亨德森（Michael Henderson）医学博士、研发主管卡尔·丹布科夫斯基（Carl Dambkowski）医学博士领衔，成员还包括首席商务与财务官丹·穆尔雷尼（Dan Mulreany）、总法律顾问马特·巴特斯（Matt Batters）法学博士以及首席人力官艾米丽·考克斯（Emily Cox）。该团队成员此前曾在阿波吉（Apogee）共事，期间推动五项由帕拉贡（Paragon）发现的资产进入临床开发阶段，直至阿波吉于2026年被艾伯维（AbbVie）以超过109亿美元的价格收购。

The expanded leadership team builds on the proven model Paragon has established with Fairmount, the investment firm that founded Paragon in 2021. Together, Fairmount and Paragon have identified promising therapeutic opportunities, developed differentiated biologics and launched new biotechnology companies around them.

扩大的领导团队依托于Paragon与Fairmount（2021年创立Paragon的投资公司）共同验证的成功模式。Fairmount与Paragon携手识别具有前景的治疗领域机会，开发差异化的生物制品，并围绕这些成果创立了新的生物技术公司。

The new leadership adds clinical development and operational expertise to Paragon's established discovery engine..

新领导层为 Paragon 成熟的发现引擎增添了临床开发和运营方面的专业知识。

'At Apogee, we learned a tremendous amount about what it takes to translate Paragon-discovered programs into clinical-stage medicines,' said Michael Henderson, M.D., Chief Executive Officer of Paragon Labs. 'We now have an opportunity to apply those lessons to clinical development, regulatory strategy and execution from the very start, as Paragon's programs take shape.

“在Apogee，我们积累了大量关于将Paragon发现的项目转化为临床阶段药物所需条件的宝贵经验，”Paragon Labs首席执行官Michael Henderson医学博士表示。“现在，随着Paragon旗下项目逐步成型，我们有机会从一开始就将这些经验应用于临床开发、监管策略及执行工作中。”

That means bringing all of these insights to make decisions even earlier, so the companies that license Paragon's most promising assets can bring them to patients even faster.'.

这意味着利用所有这些洞察更早地做出决策，从而使获得Paragon最具潜力资产授权的公司能够更快地将其推向患者。

Alaunos Therapeutics, Inc. (NASDAQ:

Alaunos Therapeutics, Inc.（纳斯达克：

TCRT

TCRT

) ('Alaunos') announced today the completion of the acquisition of Velaris Therapeutics, Inc. ('Velaris'), a privately-held biotechnology company advancing a pipeline of potentially transformative therapies for pulmonary arterial hypertension ('PAH') and related cardiopulmonary diseases. The acquisition gives the combined company a portfolio of ActRII-Fc ligand traps and complementary biologics designed to address the underlying signaling imbalances that drive remodeling of the pulmonary vasculature in multiple cardiopulmonary conditions..

（“Alaunos”）今日宣布完成对Velaris Therapeutics, Inc.（“Velaris”）的收购。Velaris是一家私营生物技术公司，致力于推进一系列具有潜在变革意义的疗法管线，用于治疗的肺动脉高压（“PAH”）及相关心肺疾病。此次收购使合并后的公司拥有ActRII-Fc配体陷阱及互补生物制品的产品组合，旨在解决驱动多种心肺疾病中肺血管重构的基础信号失衡问题。

Paragon-discovered programs have served as the foundation for nine biotechnology companies, including Apogee Therapeutics, Spyre Therapeutics, Oruka Therapeutics, Jade Biosciences, Crescent Biopharma, Korsana Biosciences, Mentari Therapeutics, Damora Therapeutics, and Velaris Therapeutics.

Paragon 发现的项目已成为九家生物技术公司的基础，包括 Apogee Therapeutics、Spyre Therapeutics、Oruka Therapeutics、Jade Biosciences、Crescent Biopharma、Korsana Biosciences、Mentari Therapeutics、Damora Therapeutics 和 Velaris Therapeutics。

For additional information, please see the Alaunos Current Report on Form 8-K filed with the Securities and Exchange Commission on October 13, 2026.

有关更多信息，请参阅阿劳诺斯公司于2026年10月13日向美国证券交易委员会提交的8-K表格当前报告。

About Paragon Labs

关于 Paragon Labs

Paragon Laboratories, Inc. ('Paragon Labs' and together with its predecessor, 'Paragon') is a biotechnology company applying cutting-edge science and technology to shape the next generation of novel, best-in-class biologics for major medical needs. The company is fueling a pipeline of transformative therapies that are positioned to be rapidly advanced into clinical development.

Paragon Laboratories, Inc.（简称“Paragon Labs”，与其前身合称“Paragon”）是一家生物技术公司，致力于应用前沿科学技术，针对重大医疗需求打造下一代创新、同类最优的生物制品。公司正推动一系列变革性疗法的研发管线，这些疗法有望快速推进至临床开发阶段。

To date, nine companies have been launched based on assets discovered by Paragon. Founded by Fairmount, Paragon is based in Waltham, MA. For more information, please visit .

迄今为止，已有九家公司基于帕拉贡发现的资产而成立。帕拉贡由费尔芒特创立，总部位于马萨诸塞州沃尔瑟姆。欲了解更多信息，请访问。

www.paragonlabs.com

www.paragonlabs.com

. Follow us on

在 上关注我们

LinkedIn

领英

.

。

About Fairmount

关于费尔芒特

Founded in 2016, Fairmount is a life sciences investment firm primarily focused on compelling new opportunities created through the firm's own drug discovery, in-licensing, and company formation efforts. For more information, visit

Fairmount 成立于2016年，是一家生命科学投资公司，主要专注于通过公司自身的药物发现、许可引进和公司组建工作所创造的极具吸引力的新机遇。欲了解更多信息，请访问

fairmount.com

fairmount.com

.

。

About Velaris Therapeutics

关于 Velaris Therapeutics

Velaris Therapeutics is a biotechnology company advancing a pipeline of potentially transformative therapies for pulmonary hypertension and related cardiopulmonary diseases. Velaris is developing ActRII-Fc ligand traps and complementary biologics designed to maximize the potential of these classes of therapies.

Velaris Therapeutics 是一家生物技术公司，致力于推进一系列针对肺动脉高压及相关心肺疾病的潜在变革性疗法。Velaris 正在开发 ActRII-Fc 配体陷阱及互补生物制剂，旨在最大化此类疗法的治疗潜力。

VLR199, with broad ligand activity, is designed to replicate clinically proven pharmacology but improving where it is not fully optimized. VLR247 and VLR258, featuring distinct ActRII extracellular domains, are designed to spare BMP-9 and BMP-10 and lower risk for hematologic adverse events. The pipeline also features VLR360, an anti-PDGF-B monoclonal antibody, which offers a complementary approach that alone or in combination with the ActRII-Fcs is designed to address the signaling imbalances that drive remodeling of the pulmonary vasculature.

VLR199 具有广泛的配体活性，旨在复制经临床验证的药理作用，并在尚未完全优化的方面加以改进。VLR247 和 VLR258 具有独特的 ActRII 胞外结构域，旨在避免影响 BMP-9 和 BMP-10，从而降低血液系统不良事件的风险。该研发管线还包括 VLR360，一种抗 PDGF-B 单克隆抗体，它提供了一种互补的治疗策略，单独或与 ActRII-Fc 融合蛋白联用，旨在解决驱动肺血管重构的信号失衡问题。

Velaris' assets were discovered by Paragon Labs. Velaris is based in Waltham, MA. For more information, visit velaristx.com..

帕拉贡实验室发现了Velaris的资产。Velaris总部位于马萨诸塞州沃尔瑟姆。欲了解更多信息，请访问velaristx.com。

Media Contact

媒体联系人

Evan Scarduffa

埃文·斯卡杜法

[email protected]

[email protected]

SOURCE Paragon Labs

来源：Paragon Labs

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示